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Lung possesses very limited regenerative capacity. Failure to maintain homeostasis of lung epithelial cell populations
has been implicated in the development of many life-threatening pulmonary diseases leading to substantial morbidity
and mortality worldwide, and currently there is no known cure for these end-stage pulmonary diseases. Embryonic
stem cells (ESCs) and somatic cell-derived induced pluripotent stem cells (iPSCs) possess unlimited self-renewal capacity
and great potential to differentiate to various cell types of three embryonic germ layers (ectodermal, mesodermal, and
endodermal). Therapeutic use of human ESC/iPSC-derived lung progenitor cells for regeneration of injured or diseased
lungs will have an enormous clinical impact. This article provides an overview of recent advances in research on
pluripotent stem cells in lung tissue regeneration and discusses technical challenges that must be overcome for
their clinical applications in the future.
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Pulmonary diseases are one leading cause of morbidity
and mortality worldwide. Currently available treatments
can only alleviate symptoms or delay disease progression
within a limited time range for patients with end-stage
pulmonary diseases. Lung transplantation remains the only
definitive treatment for many end-stage patients, yet its
clinical impact is limited by shortage of suitable donor
lungs and transplant rejection. More than 10% patients on
waiting list die each year before transplantation [1], and
the 5-year survival rate of recipients is only approximately
50% [2,3]. Recent findings in stem cell research have
attracted a lot of interest to developing reliable means
to regenerate injured/diseased lungs. Studies on animal
lung injury models have shown that there are divergent
progenitor populations responsible for maintaining homeo-
stasis of lung epithelia in anatomically different regions.
However, technical difficulty to isolate and characterize
these progenitor types due to the complex lung structure
continues to hinder the understanding of the role of en-
dogenous regenerative pathways in lung tissue maintenance* Correspondence: dachun.wang@uth.tmc.edu
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reproduction in any medium, provided the origand repair in response to injuries. During the past several
years, significant progress has been made in purification
and characterization of lung progenitor cells derived from
embryonic stem cells (ESCs) and induced pluripotent stem
cells (iPSCs). These ESC/iPSC-derived lung progenitor cells
hold great promise for understanding lung stem cell biology
and disease processes, developing cell-based therapies
for incurable pulmonary diseases, and generating bioen-
gineered lungs. This review will summarize current ad-
vances in lung stem cell research and discuss technical
challenges for possible therapeutic use of pluripotent
stem cells in lung tissue regeneration in the future.Review
Pulmonary epithelia and stem/progenitor cell types
The lung is a complex organ composed of anatomically
different regions including trachea, bronchi, bronchioles
and alveoli, each lined with functionally and structurally
distinct epithelium. The pseudostratified epithelium cov-
ering trachea and bronchi is composed predominantly of
basal, mucous secretory goblet cells and ciliated cells, along
with a few discrete pulmonary neuroendocrine cells. In
bronchioles, especially in the respiratory bronchioles,
non-ciliated secretory Clara cells cover most of the surface
area, although the less frequent ciliated cells also reside ins is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
inal work is properly credited.
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transitional zone between large airways and alveoli imply
that they may play an important role in coordinating
the functions of the conducting airways and the gas-
exchanging region. The alveolar epithelium covers more
than 99% of the internal surface area of the lung and is
composed of the alveolar epithelial type I cells (ATICs)
and type II cells (ATIICs). ATICs are large and flat, cov-
ering about 95% of the gas-exchanging alveoli; together
with endothelium of surrounding capillaries, they form a
very thin blood-air interface essential for O2/CO2 exchange.
In contrast, ATIICs are small, cuboidal cells, and play an
important role in maintenance of alveolar homeostasis.
As pulmonary epithelia are constantly exposed to in-
jurious stimuli from the environment, the lung needs to
generate new cells to replenish injured and aged epithe-
lial cells for maintaining normal structure and function.
It is known that the endogenous repair capacity of the
lung is relative low [4-7] and may fail after repeated
challenges, leading to development of life-threatening
pulmonary diseases such as asthma, chronic obstructive
pulmonary disease, and idiopathic pulmonary fibrosis.
Due to lung structural complexity with cellular diversity
and slow epithelial cell turnover rates, it is still a challenge
to isolate and characterize lung stem/progenitor cells for
exploring the lung disease processes and endogenous re-
pair mechanisms. To date, whether there are undifferenti-
ated multipotent stem cells with the ability to self-renew
indefinitely in lung is controversial. Injuries to mobilize
stem cells for tracking DNA label-retaining cells (LRCs)
are a key approach to identifying stem/progenitor cell
compartment in distinct lung regions. There is mounting
evidence showing that local progenitor cells function to
renew injured and aged epithelial cells in anatomically dif-
ferent regions [8-11]. In the trachea and larger airways,
basal cells have traditionally been considered as progenitor
cells, with the capacity for proliferating and differentiating
into basal, ciliated, and goblet cells [12,13]. In human, the
large airway epithelium is more pseudostratified, and there
are parabasal cells located right above the basal cells.
Because parabasal cells express high level of proliferation
marker MIB-1, they are thought to function as transient
amplifying (TA) cells derived from basal cells in the larger
airways [14,15]. In addition, subcutaneous transplantation
experiments have shown that tracheal grandular cells can
repopulate tracheal epithelium. In SO2-induced tracheal
injury model of mice, LRCs accumulated in submucosal
gland ducts lasted longer than those in tracheal epithelium
[16,17], suggesting that submucosal gland ducts may
harbor relatively primitive precursor cells for tracheal
epithelium.
In distal lung, injury studies using naphthalene, a Clara
cell-specific toxic agent, to deplete Clara cells have revealed
that two populations of progenitor cells are responsible forthe maintenance of bronchiolar epithelium: the abundant
facultative TA Clara cells, and a subset of variant Clara
cells that is cytochrome P450 2 F2 negative and stem
cell antigen positive [18-22]. These variant Clara cells
are naphthalene-resistant and express Clara cell-specific
marker CCSP. They reside in discrete groups at the
bronchioalveolar duct junction (BADJ) and the branch
point-associated neuroepithelial bodies. It has been dem-
onstrated that the variant Clara cells located at BADJ also
express ATIIC-specific surfactant protein C (SPC) [23,24].
These cells appear to possess the ability to proliferate and
differentiate into both bronchiolar and alveolar epithelial
cells in vitro, and may be important in the maintenance of
both bronchiolar and alveolar epithelial cell populations
[23]. Studies using mouse injury model have shown
that ATIICs possess proliferative capacity and play an
important role during the re-epithelialization of alveoli
after lung injury. In addition, multipotent stem cells
with the potential of generating distal lung-like tissue
in vivo have been isolated from adult lungs of sheep
and rats [25]. More recently, undifferentiated human
lung stem cells (hLSCs) were identified in distal lungs.
These cells are antigen c-kit+ and have the capacity to
generate human bronchioles, alveoli and pulmonary ves-
sels after injected into injured mouse lungs [26]. These
studies provide strong evidence for the existence of distal
lung stem cells, yet their relationship with Clara and
ATIICs is still unclear.
Lung epithelial progenitor cells derived from ESCs
Strategies to derive ESCs into lung epithelial progenitor cells
The ESCs isolated from the inner cell mass of blastocyst-
stage embryos are undifferentiated, pluripotent cells
[27,28], and can be induced to differentiate in vitro into a
wide range of different cell types [29-36]. ESC-derived
lung stem/progenitor cells are a promising cell source for
exploring therapeutic methods treating lung injuries and
pulmonary genetic disorders. Due to the fact that most
lung stem/progenitor cell types as well as their hierarchy
have not been well characterized, progress in development
of procedures to derive ESCs into lung stem/progenitor
cells has been slow, and the mechanisms underlying the
differentiation of ESCs into large lung airway epithelial
cells remains elusive. It has been demonstrated that ESCs
can be differentiated into Clara cells [37,38] and ATIICs
via embryonic body (EB) formation or co-culture with
pulmonary mesenchyme [39-41]. However, these spontan-
eous differentiation procedures are not efficient, generat-
ing only a very small percentage of ESC-derived lung cells
[42]. Recently, procedures to enrich definitive endoderm
for effective differentiation of ESCs into ATIICs have been
developed by using a growth factor cocktail or a lung-
specific cell-conditioned medium [43], but are not yet
successful in generating a homogenous population of
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ATIICs from ESCs was demonstrated by ATIIC-specific
SPC expression and morphological appearance of lamellar
bodies. It remains unclear whether these ESC-derived
ATIICs possess normal biological function. In addition,
these differentiated cultures generate a mixed population
of cell derivatives and may contain the remaining pluripo-
tent cells, which is not suitable for transplantation because
they carry a significant risk of producing teratomas after
transplantation in vivo.
In order to obtain transplantable ESC-derived ATIICs,
our laboratory has developed a reliable procedure to gener-
ate stably transfected human ESC (hESC) lines containing a
single copy of ATIIC-specific SPC promoter/neomycinR
(NEOR) transgene [44]. As SPC is specifically expressed by
ATIICs, only hESC-derived ATIICs can express NEOR and
survive in G418 selected cultures. Without the need of EB
formation, these hESC lines can be selectively differentiated
into an essentially pure population of ATIICs (hES-ATIICs)
when cultured on matrigel coated dishes in the presence of
G418. These hES-ATIICs show the biological features and
morphological characteristics of normal ATIICs, including
lamellar body formation, expression of surfactant proteins,
and the ability to proliferate and differentiate into ATICs
in vitro. Hence, they can serve as a transplantable source
of ATIICs for the exploration of their possible clinical ap-
plication in the future [45].
Characterization of ESC-derived ATIICs in vivo
Bleomycin (BLM)-induced alveolar injury is well charac-
terized in mice [46,47], and has been used as a model
to test therapeutic potential of hES-ATIICs [45]. When
transplanted into SCID mice on day 1 or 2 after exposure
to BLM, a substantial number of hES-ATIICs remained in
the injured lungs; approximately 34% of these expressed
ATIC markers on day 10 after BLM challenge, suggesting
that these transplanted hES-ATIICs had differentiated into
ATICs in vivo [45]. Lung injury was abrogated in mice
transplanted with hES-ATIICs, demonstrated by signifi-
cantly decreased collagen deposition and complete recov-
ery of body weight and arterial blood oxygen levels. It was
also noted that numerous endogenous mouse ATIICs
survived in the BLM-injured lungs of hES-ATIIC trans-
planted mice, but not in BLM-injured lungs receiving
monocytes or normal saline, suggesting that structurally
engrafted hES-ATIICs may provide an appropriate signal
microenvironment via their paracrine effect in activating
endogenous repair. Thus, structural engraftment and
differentiation of hES-ATIICs coupled with activated
endogenous ATIICs can lead to robust re-epithelialization
of injured alveoli. Further investigations are needed to
characterize the signaling communication between ATIICs
for maintaining alveolar homeostasis. We also found that
BLM-injured mice transplanted with hES-ATIICs survivedas normal mice without experiencing tumorigenic side
effects, demonstrating that genetic selection is an effect-
ive approach to generating transplantable ESC-derived
lung stem/progenitor cells. However, random transgene
insertion into the chromosomal DNA may cause unpre-
dicted critical gene dysfunction. In addition, only approxi-
mately 5% hES-ATIICs remained in the BLM-injured lungs
10 months after transplantation. Poor long-term retention/
survival of engrafted hES-ATIICs in injured lungs of SCID
mice [45] indicates that the mouse lung may reject
hES-ATIICs or fail to provide an appropriate micro-
environment for hES-ATIICs to rebuild the progenitor
cell pools after injury. Therefore, mouse ESCs (mESCs)
should be used instead to explore the potential long-term
therapeutic benefit of ESC-derived ATIICs in mice injury
models. More recently, our laboratory has generated gen-
etically modified mESC lines harboring a single copy of
ATIIC-specific NEOR transgene in Rosa 26 gene locus
[48]. These random genetic insertion-free mESC lines can
be directed to differentiate into a homogenous population
of functional ATIICs, providing a reliable source of cells
for further characterization of ESC-derived ATIICs in
mice lung injury models.
Lung epithelial progenitor cells derived from iPSCs
The methodology for reprogramming of somatic cells into
iPSCs with defined reprogramming factors (Oct4, Sox2,
cMyc and Klf4) was established by Yamanaka’s group in
2006 [49]. As renewable source of autologous, disease-
specific cells, iPSCs hold great promise in regenerative
medicine for modeling diseases, screening drugs and de-
veloping cell-based therapeutic strategies. Initially, the
technique uses retrovirus or lentivirus to deliver necessary
reprogramming factors for successfully reprogramming
[49-51]. However, as random integration of multiple
copies of each transgene to over-express reprogramming
factors for reprogramming is a stochastic process, the gen-
erated iPSC lines exhibit considerable phenotypic variation
and may have unpredictable critical gene dysfunction. In
addition, constant expression of reprogramming transgenes
may result in deleterious outcomes in which the derived
iPSCs could develop into tumor or lose their pluripotency.
For safety improvement, many alternative techniques have
been developed by using non-integrating vectors [52-55]
or PiggyBac transposon system [56] to avoid or eliminate
insertional mutagenesis, yet the application of these
methods is limited by the impractically low reprogramming
efficiency. Recently, iPSCs have been generated by direct
delivery of recombinant proteins, RNAs, or microRNAs
[57-59]. These nongenetic techniques allow generating
genetic integration-free iPSCs, yet they require special ex-
pertise for preparing proteins, RNA and mature microRNA
and need multiple times of transduction/transfection
for reprogramming, and the reprogramming process is
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though efficient generation of genetic integration-free
and exogenous reprogramming-factor-free iPSCs continues
to be a challenge, a series of animal studies have dem-
onstrated the potential clinical value of iPSC-derived
progenitor cells in treatment of congenital hypomyelina-
tion, spinal cord injury, diabetes, and Parkinson’s disease
[60-63]. Recently, human lung disease-specific iPSC lines
associated with either cystic fibrosis or alpha-1 antitrypsin
deficiency-related emphysema have been generated with a
single excisable lentiviral vector [64]. Although the derived
iPSC lines could be useful for lung disease modeling, the
use of a viral vector for reprogramming and the part
of DNA sequence left behind at unknown site(s) after
removal of transgenes are potential drawbacks. In addition,
difficulty to obtain iPSC derived transplantable cell types is
still a major obstacle to developing clinical application of
iPSCs.
In order to generate random-insertion-free and ex-
ogenous reprogramming-factor-free hiPSCs that can
be selectively differentiated into pure populations of
ATIICs without the need of any additional treatment or
genetic modification, our laboratory developed a single site-
specific targeting vector, which harbors the reprogramming
transgenes controlled by Tet-On inducible gene expression
system, ATIIC-specific NEOR transgene, and loxP targeting
sequence [65]. With this non-viral targeting vector, all re-
quired transgenes can be inserted into a site immediately
downstream of β-2-microglobulin (B2M) gene locus
without causing B2M dysfunction. The reprogramming
transgenes can be induced to express for efficient repro-
gramming of human skin fibroblast, and subsequently
removed to obtain genetic integration-free and exogen-
ous reprogramming-factor-free hiPSC lines. Because the
derived hiPSCs contain the ATIIC-specific NEOR trans-
gene, they can be selectively differentiated into an essen-
tially pure population of functional ATIICs after cultured
on matrigel-coated dishes in differentiation medium (DM)
with 20 μg/ml of G418 for 14 days [65]. The selective dif-
ferentiation procedure for generation of hiPSC-derived
ATIICs is illustrated in Figure 1. The SPC+ cells can be
enriched as early as on day 10. It was found that these
early derived SPC+ cells did not express surfactant protein
A (SPA) and B (SPB), but possessed robustly proliferative
capacity, suggesting that they may be early primitive
progenitor cell type(s). On day 14, the hiPSC-derived
SPC+ cells (hiPSC-ATIICs), which did not express CCSP,
expressed thyroid transcription factor one (TTF1) and
surfactant proteins with typical ultra-structure of ATIICs
(Figure 2). We showed that these hiPSC-ATIICs possess
regulatable capacity for synthesizing and secreting surfac-
tant proteins and lipids as primary human ATIICs. Like
hES-ATIICs discussed above, the hiPSC-ATIICs have
great potentials in engrafting and differentiating intoATICs in vivo for re-population of BLM-injured alveoli
and repair of damaged pulmonary function. This is a
one-step site-specific genetic modification. This novel
strategy makes it possible for the first time to generate
lung disease-specific hiPSC-ATIICs for exploring their
clinical application and modeling alveolar diseases.
Lung tissue bioengineering
Proof-of-principle studies in tissue engineering have
strongly demonstrated the potential of engineered func-
tional organs such as heart, liver and kidney [66-68]. Gen-
eration of engineered lungs is an attractive prospect for
the treatment of end-stage pulmonary diseases. Several
groups have been able to culture fetal and adult lung cells
in three-dimensional culture systems with synthetic scaf-
folds for creating engineered lung tissue ex vivo [69-73].
While the natural and synthetic scaffolds are capable of
supporting differentiation of ESCs into CCSP+ and SPC+
cells, it is not clear whether these cells are functional distal
airway and alveolar cell types. The published data have
shown the potential of Gelfoam sponge scaffold seeded
with fetal rat lung cells in forming alveolus-like structure
in vivo [73]. However, whether the engineered tissue is
capable of ventilation-perfusion for gas exchange remains
to be investigated.
Recently, substantial advances have been made in engin-
eering functional trachea using an artificial matrix and a
decellularized, cadaveric scaffold [74,75]. Macchiarini et al.
developed a tissue-engineering procedure to generate a
trachea by seeding recipient’s airway epithelial cells and
chondrocytes onto a decellularized, cadaveric trachea scaf-
fold within a custom bioreactor. The engineered airway
segment was then used to replace the left main bronchus
with malacia to restore the end-staged patient’s pulmonary
function without the need of immunosuppressive drugs.
The 5-year follow-up results showed that the patient had
a normal life, suggesting that the tissue-engineering strat-
egy is safe and promising in generating engineered trachea
for autologous transplantation [76].
It is intrinsically difficult to decellularize and recellular-
ize whole lung tissue to recapitulate its complex structure.
Despite this, significant progresses have also been made in
using a whole decellularized lung as a scaffold to generate
engineered lung [77,78]. The fully decellularized lung
retains its native architecture with acellular vasculature,
airways and alveoli, and appears superior to other simple
bioartificial scaffolds to support differentiation and recel-
lularization of pluripotent stem cells. The cultured lung
epithelial and vascular endothelial cells in the decellular-
ized lung scaffold can efficiently repopulate the epithelial
and vascular structures in a custom bioreactor to generate
engineered lung with the potential for ventilation and gas
exchange in vivo. However, due to the fact that some of
decellularized areas are not completely recellularized to
Figure 1 Diagram of hiPSC differentiation. The hiPSCs were cultured on matrigel-coated plates in DM containing 20 μg/ml of G418 for 14 days.
The SPC positive cells were observed in the differentiating cultures at a very early time point (day 5), and can be enriched into a homogenous
population (>99%) with robust proliferation capacity on day 10. The hiPSC-derived ATIICs were observed in the cultures on day 14, which
expressed TTF1 and surfactant proteins (SPA, SPB, and SPC).
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blood cells and thrombus formations in the airspaces of
engineered lungs after transplantation. Although the
engineered lungs participate gas exchange in vivo for
only short time intervals, these significant advances
demonstrate the feasibility of using whole decellularized,
cadaveric lungs as scaffolds for generation of functionally
engineered lungs for transplantation.
Using patient-derived iPSCs to recellularize the decellu-
larized, cadaveric lung scaffolds that lack donor cells ex-
pressing alloantigens is expected to generate functionally
engineered lungs for “autologous” transplantation. Like
ESCs, iPSCs have the potential to differentiate into many
different tissue cell types. Thus, preventing nonspecific
differentiation and overgrowth of iPSCs will be a chal-
lenge for generating engineered lungs. Recently, the
relatively primitive c-kit+hLSCs have been identified.
The c-kit+hLSCs are lung-specific and have the capacity
for generating distal lung structure, including bronchioles,Figure 2 Electron micrographs showed well-developed lamellar bodie
ATIICs; the immunofluorescent staining images demonstrated that G4
human ATIICs did.alveoli and blood vessels in vivo [26]. Although the ability
of c-kit+hLSCs to generate larger airway still remains to be
investigated, hiPSC-derived c-kit+hLSCs is considered a
promising source of cells that can be used to recellularize
the decellularized lung scaffold. Developing a strategy to
direct differentiation of patient-derived iPSCs into the
more primitive c-kit+hLSCs that can be used to recellular-
ize the decellularized lung scaffold to reconstitute its com-
plex structure with orchestrated and coordinated epithelia
and endothelium is an attractive prospect.
Conclusion
Potential application of lung stem/progenitor cell types
derived from iPSCs and ESCs holds great promise in
modeling pulmonary diseases and developing cell-based
therapies for treatment of severe lung diseases. Because
ESCs and their derivatives express alloantigens, including
MHC class I molecules that are primary targets for im-
mune rejection by self-recognizing T cells, development ofs (LBs) in G418-selected hiPSC-ATIICs, as in the control human
18-selected hiPSC-ATIICs expressed SPA, SPB and SPC as control
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major limitation to their clinical application. Patient-
derived iPSCs are conceivably genetically identical to
the patient. However, reprogramming may result in a
number of abnormal gene expressions in iPSC-derived
cells, causing immune rejection in the syngeneic recip-
ients as reported by Zhao et al. [79]. Technologies for
generating iPSCs need to be further improved in order to
obtain “clinical grade” iPSCs. Whether the novel strategy
that we have developed to generate the genetic integration-
free and exogenous reprogramming factor-free hiPSC lines
may cause abnormal gene expression or defects needs to be
further evaluated. As ESCs are reliable and versatile for
generating many different tissue cell types, it is an appealing
option to generate a “universal” hESC line with significantly
reduced expression of MHC molecules. It is hoped that
lung stem/progenitor cells derived from a “universal” hESC
line can be transplanted without evoking robust immune
response from HLA class I mismatched recipients, and thus
can be used to generate engineered lungs for clinical use
in the future.
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